For anyone in Tanus searching for CJC-1295, the key fact to understand is that this compound moves through online research channels. What this means for Tanus researchers is that geography is secondary to your ability to assess COA data — and those quality checks are within reach of all serious researchers. Vendors worth sourcing from openly share batch-matched Certificates of Analysis containing HPLC chromatograms, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the specific lot you are purchasing. Use this guide to evaluate CJC-1295 vendors rigorously — the framework here work regardless of your location.
CJC-1295: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Tanus comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
CJC-1295 Purchasing Guide
The first step for any Tanus researcher sourcing CJC-1295 is finding vendors with verified community track records — organic rankings are no guide to actual CJC-1295 quality. The HPLC purity trace is the most important document in the COA: it should show a large primary peak representing CJC-1295, with minimal secondary peaks representing impurities — purity should be stated as ≥98%. Negative indicators in CJC-1295 vendor evaluation: prices significantly below market average, unclear production details, no community presence, and COAs that lack endotoxin data. Keep lyophilised CJC-1295 at minus 20 degrees Celsius until ready to use; reconstitute only the amount needed for the near-term protocol and store the rest at −20°C.
Order CJC-1295 — ships to Tanus
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not been through the clinical trial process required for pharmaceutical approval — its safety profile is defined by animal study data and limited human studies. Proper handling of CJC-1295 requires careful sterile procedure — prep pad-cleaned septum, single-use needles, uncontaminated workspace — and cold chain maintenance from receipt through use. Endotoxin testing in the CJC-1295 COA is absolutely required — gram-negative bacterial endotoxins can trigger serious inflammatory reactions at very low concentrations, and no cost saving makes omitting this acceptable. Protocol documentation — keeping clear records of compound, timing, and method — is a research best practice for CJC-1295 that ensures unusual findings can be explained.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
